Heplisav-B may not get off to a particularly roaring start, however. The company, after all, lacks the experience and financial resources necessary to compete on even-footing against either Glaxo or Merck. In fact, Wall Street's consensus estimate has Heplisav-B generating a rather meager $53 million in sales this year.